with $39.0 million for the year ended December 31, 2007. Net sales of once-daily LUVOX CR(R) (fluvoxamine maleate) Extended-Release Capsules, launched in April 2008, were $3.1 million for the fourth quarter of 2008 and $5.7 million for the nine-month By: Christian Yost April 1, 2009 Ever since the earliest days of human-cat interactions, cats have had a reputation for being mystical, spiritual beings, either divine or possessed. It isn't hard to understand why. Cats have the propensity to gaze unblinking in peoples' eyes, to appear to see things ... Women experience depression about twice as often as men. Hormonal factors may contribute to the increased rate of depression in women particularly such factors as menstrual cycle changes, pregnancy, miscarriage, postpartum period, pre-menopause, and menopause. Although men are less likely to suffer ...
Everything is so unstable these days. I discovered last night, I felt strange, certainly, but after I’d relaxed in bed next to my wife, reading the end of Ralph Ketcham’s bio of James Madison, my wife directed me to get a little, white lynx-point named Molly off of the cable box, and the...
El consejero delegado de Lilly, John Lechleiter, debe sentirse estos días como monsieur Sans-délai, el desconcertado y atribulado, protagonista de 'Vuelva usted mañana', el famoso artículo de Larra, que parece mantener su vigencia después de tantos años. Y, aunque más por prudencia que por pereza, eso es lo que la FDA ha venido a decirle a Lilly por segunda vez en tres meses: 'Vuelva usted mañana'. El regulador norteamericano ha decidido retrasar de nuevo la aprobación de Effient (prasugrel DCI)